Drug Trial Radar · NCT06613100
Evaluation of Neoadjuvant Xaluritamig in Localized Prostate Cancer
Last checked: Nov 20, 2026Latest source record: Jul 31, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
40
Planned (sponsor's estimate)
Start
Nov 25, 2024
Primary completion
Feb 17, 2027
Study completion Mar 4, 2030
Sponsor
- Lead sponsor
- AmgenAmgen (AMGN)
- Sponsor type
- Industry
- First posted
- Sep 25, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objectives of this study are to evaluate the safety and tolerability of xaluritamig administered as monotherapy or in combination with an oral Gonadotropin-releasing Hormone (GnRH) antagonist in the neoadjuvant setting followed by radical prostatectomy, and to evaluate the feasibility and safety of a radical prostatectomy following xaluritamig administered as monotherapy or in combination with an oral GnRH antagonist in the neoadjuvant setting.
Conditions
- Prostate Cancer
Interventions
XaluritamigDrug
Intravenous (IV) infusion
GnRH AntagonistDrug
Oral administration
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants who Experienced Treatment-emergent Adverse EventsTime frame: Up to 45 months
- Number of Participants who Experienced Treatment-related Adverse EventsTime frame: Up to 28 months
- Number of Participants who Received Radical Prostatectomy After Completing Xaluritamig TreatmentTime frame: Up to 25 months
- Number of Participants who Experienced Complications of Radical Prostatectomy According to Clavien-Dindo ClassificationTime frame: Up to 28 months
Locations
9 sites in 2 countries. Site status is shown where the registry gives one.
University of California San Francisco
San Francisco, California · Recruiting
Washington University
St Louis, Missouri · Recruiting
The Ohio State University
Columbus, Ohio · Recruiting
Thomas Jefferson University
Philadelphia, Pennsylvania · Recruiting
Carolina Urologic Research Center
Myrtle Beach, South Carolina · Recruiting
Fred Hutchinson Cancer Center
Seattle, Washington · Recruiting
Medical College of Wisconsin
Milwaukee, Wisconsin · Recruiting
Universitaetsklinikum Essen
Essen, Germany · Recruiting
Universitaetsklinikum Hamburg Eppendorf
Hamburg, Germany · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.